23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

23andMe reports strong Q1 growth, focuses on profitability and partnerships

23andMe demonstrated strong growth in customer base and subscription members, with a focus on margin expansion and revenue growth. The company faces challenges in achieving profitability but has opportunities to leverage genetics for healthcare transformation and pursue partnerships. Overall, 23andMe's performance reflects a strategic focus on growth and financial discipline.

23andMe reports Q1 revenue decline, focuses on therapeutics and AI

Despite a decrease in Q1 2023 revenue, 23andMe demonstrated strength in its therapeutics business and strategic pricing initiatives. The company faces challenges with significant workforce reduction and higher operating expenses but has opportunities in advancing immuno-oncology assets and leveraging AI advancements.

23andMe reports revenue growth and strategic initiatives for future expansion

Overall, 23andMe's Q3 performance showcased growth and innovation in both consumer and therapeutic segments. While facing challenges with increased expenses and a net loss, the company's raised full-year guidance and strategic initiatives present opportunities for future expansion and profitability.

23andMe reports revenue growth and strategic healthcare integration plans

23andMe's Q4 2023 earnings call showcased strong revenue growth, new health report offerings, and advancements in therapeutics. Despite financial projections indicating a net loss and EBITDA deficit for FY 2024, the company remains focused on expanding margins and capital efficiency. Integration of telehealth services and personalized care present promising opportunities for future growth.

23andMe reports Q1 revenue decline, eyes growth in therapeutics

23andMe navigated challenges with workforce reductions and revenue decline, focusing on margin improvement and cost discipline. The company aims to capitalize on opportunities in therapeutics and consumer businesses through strategic initiatives. With a strong cash position and guidance for improvement in adjusted EBITDA deficit, 23andMe is positioning for future growth.

23andMe reports Q2 revenue of $50M, focuses on margin expansion

23andMe's Q2 2024 performance showed revenue of $50 million with a net loss of $75 million, emphasizing margin expansion.
Strengths include new subscription offerings, FDA clearances, promising therapeutics pipeline, and data security focus.
Challenges include net losses, adjusted EBITDA deficit, and updated FY 2024 guidance reflecting uncertainties.
Opportunities lie in expanding subscription services, enhancing product offerings, and leveraging collaborations for growth.

23andMe reports Q3 revenue decline, focuses on strategic growth

23andMe faced revenue decline and increased expenses, leading to a significant net loss and revised guidance for fiscal year 2024.
Despite challenges, the company showcased strengths in strategic progress, therapeutics advancements, and extended collaborations.
Opportunities lie in margin expansion, cash flow profitability, and leveraging consumer offerings and partnerships for future growth.

23andMe reports strong revenue growth and strategic shifts for growth

23andMe showcased strong performance in membership revenue growth and advancements in research and therapeutics, despite challenges in revenue and operating expenses.
The company's strategic shift towards high-value programs and partnerships with GSK position it well for long-term growth and innovation in the genetic testing and healthcare space.
While facing challenges in cost management and revenue generation, 23andMe has opportunities to optimize operations, drive growth through new programs, and address compliance issues.
Overall, 23andMe's focus on innovation, strategic collaborations, and operational efficiency sets the stage for navigating challenges and capitalizing on growth opportunities in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

Chu brings over two decades of experience in product management, design and strategy, as well as expertise with navigating complex industries Chu brings over two decades of experience in product management, design and strategy, as well as expertise with navigating complex industries

Daniel Chu Joins 23andMe as Chief Product Officer

Ardelyx

Avaya Holdings

Nutex Health Inc

Penny stocks to buy according to top money managers. The post 4 Hot Penny Stocks To Buy Now According To Top Hedge Funds appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Hot Penny Stocks To Buy Now According To Top Hedge Funds

Latch

I own both of these companies but wouldn't put any more money into them today.

2 Ex-SPACs I Wouldn't Touch Right Now

23andMe is seeing its revenue decline as operational expenses accelerate. The company is burning cash at an alarming rate with no signs of slowing down.

23andMe: Treacherous Path To Profitability

Genetics testing provider 23andMe said its chief financial officer will leave the company next month after four years with the company. Steve Schoch notified 23andMe of his resignation earlier this week, effective Sep. 1, according to an SEC filing.

23andMe Seeks New CFO

Source: nevodka / Shutterstock.com 23andMe (NASDAQ: ME ) is preparing for a major change at the executive level. Today, the firm announced that CFO Steven Schoch is planning to resign.

CFO Transition Rocks 23andMe (ME) Stock

Shares of 23andMe Holding Co. ME, +1.95% were falling more than 7% in premarket trading Friday after the DNA-testing company disclosed that Chief Financial Officer Stevem Schoch was resigning from the company. He will stop being 23andMe's "principal financial officer and principal accounting officer" as of Sept.

23andMe stock falls after company says CFO to depart

Enovix Corporation

Marqeta

Sonos

Trupanion

Investors continue to slowly move away from worries about the economy, inflation, and interest rates, sending growth stocks higher. It's not all good news and positivity, though.

Despite Some Big Losers, These Growth Stocks Are Keeping the Nasdaq Bull Market Going

23andMe Holding Co. (NASDAQ:ME ) Q1 2023 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Wade Walke - Vice President, Investor Relations Anne Wojcicki - Chief Executive Officer & Co-Founder Steve Schoch - Chief Financial Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants Tiago Fauth - Credit Suisse David Lebowitz - Citi Operator Good morning, and welcome to 23andMe's Fiscal 2023 First Quarter Financial Results Conference Call. As a reminder this call is being recorded.

23andMe Holding Co. (ME) CEO Anne Wojcicki on Q1 2023 Results - Earnings Call Transcript

First quarter revenue grew 9% to $64.5 million Consumer revenue grew 17% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance

23andMe Reports FY2023 First Quarter Financial Results

Trading volume is surging in the hours leading up to its quarterly financial report.

Why 23andMe Stock Jumped Higher on Monday

SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2023 (FY2023) first quarter after the market closes on Monday, August 8, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress.

23andMe to Report FY2023 First Quarter Financial Results

Bright Green Corp

StealthGas

Check these three penny stocks out for your watchlist The post Best Penny Stocks to Watch in the Second Half of June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch in the Second Half of June

The genetics company misses on both the top and bottom lines in its fourth quarter.

Why 23andMe Stock Was Lagging the Market Today

23andMe Holding Co. (NASDAQ:ME ) Q4 2022 Earnings Conference Call May 26, 2022 4:30 PM ET Company Participants Wade Walke - Vice President of Investor Relations Anne Wojcicki - Co-Founder and Chief Executive Officer Kenneth Hillan - Chief Therapeutics Officer Steve Schoch - Chief Financial Officer Conference Call Participants Tiago Fauth - Credit Suisse AG Daniel Grosslight - Citigroup Inc. Operator Good morning, and welcome to the 23andMe's Fiscal Year 2022 Fourth Quarter and Year-End Financial Results Conference Call. As a reminder, this call is being recorded.

23andMe Holding Co. (ME) CEO Anne Wojcicki on Q4 2022 Results - Earnings Call Transcript

Shares of 23andMe Holding Co. ME, fell almost 7% in after-hours trading after the genetic-testing company saw its loss widen for the fiscal fourth quarter, and issued guidance that assumes the loss will widen further.

23andMe stock falls on widening loss

Achieved FY2022 financial guidance Fourth quarter and full year revenues of $101 million and $272 million representing 14% and 11% increases over prior year, respectively New genomic health services expected in FY2023 Webcast today, May 26, 2022, at 4:30 p.m. Eastern Time

23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results

Clean Energy Fuels

HUYA Inc - ADR

IMAC Holdings Inc

Mereo Biopharma Group Plc - ADR

Top Wall Street Investors Own These 5 Penny Stocks. Are They A Buy Now?

Best Penny Stocks To Buy? Einhorn, Lynch, Cohen & Dalio Own These 5

SUNNYVALE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) fourth quarter and full year after the market closes on Thursday, May 26, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time to discuss the quarter's financial results and report on business progress.

23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results

A better understanding of genes could dramatically improve healthcare.

23andMe CEO Anne Wojcicki on Bringing Health Information Directly to People

The company's drug development program is the major key to success.

This Exciting Biotech Stock Could Be Your Next 10-Bagger

Offerpad Solutions

These stocks are down by 50% or more from the highs but could be big winners for patient investors.

2 Beaten-Down SPACs That Could Be Long-Term Home Runs

SUNNYVALE, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company with a mission to help people access, understand, and benefit from the human genome, today announced that it will present data related to its wholly owned 23ME-00610 immuno-oncology program at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting being held April 8-13, 2022 in New Orleans, Louisiana.

23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting

The Beachbody Co.

Evolv Technologies Holdings

Velo3D

Attaching a celebrity's name to a SPAC is a good way to get people excited, but these SPACs all failed despite the support of some big names. The post These 5 SPACs All Plummeted After Celebrities Backed Them appeared first on InvestorPlace.

These 5 SPACs All Plummeted After Celebrities Backed Them

SUNNYVALE, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be presenting at the Cowen 42nd Annual Health Care Conference on March 7, 2022 at 2:50 p.m. Eastern Time.

News for 23andMe Stock (ME)